Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice

BACKGROUND: Several trials evaluated the role of intensive regimens, made of triplet chemotherapies plus bevacizumab, as first-line treatment for patients with metastatic colorectal cancer (mCRC). We previously reported, in a Phase II prospective study, the efficacy and the tolerability of FIrB/FOx...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortellini, Alessio, Cannita, Katia, Parisi, Alessandro, Lanfiuti Baldi, Paola, Venditti, Olga, D’Orazio, Carla, Dal Mas, Antonella, Calvisi, Giuseppe, Giordano, Aldo V, Vicentini, Vincenzo, Vicentini, Roberto, Felicioni, Lara, Marchetti, Antonio, Buttitta, Fiamma, Russo, Antonio, Ficorella, Corrado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438145/
https://www.ncbi.nlm.nih.gov/pubmed/30988620
http://dx.doi.org/10.2147/OTT.S194745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438145/
https://www.ncbi.nlm.nih.gov/pubmed/30988620
http://dx.doi.org/10.2147/OTT.S194745

Ejemplares similares